Thermo Fisher: Strong Foundation For Growth


  • Thermo Fisher has a very attractive product mix and market distribution.
  • Strong performance across pharma, biotech, industrial, and diagnostics segments will continue well into the future.
  • Decreasing revenue from COVID-related products will be more than compensated by other segments of the company in the future.

Mature female virologist wearing eyeglasses experimenting in laboratory

Maskot/DigitalVision via Getty Images

Investment Thesis

Thermo Fisher Scientific (NYSE:TMO) is the world leader in manufacturing scientific devices, instruments, diagnostic products, and related services. The company offers a great combination of stability and growth, and has a highly complementary product mix and favorable

Disaggregated Revenue

Disaggregated Revenue (SEC Filings)

Profitability Metric

Profitability Metric (Seeking Alpha)

Price Target


Base Case

$672.88 12%

Bullish Case

$724.63 20%

Very Bullish Case

$779.78 30%

Weighting TMO
Economic Moat Strength 30% 5
Financial Strength 30% 4
Growth Rate vs. Sector 15% 4
Margin of Safety 15% 4
Sector Outlook 10% 4
Overall 4.3

Disclosure: I/we have a beneficial long position in the shares of TMO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Leave a Reply

Your email address will not be published. Required fields are marked *